Among the various price targets circulating for Corcept Therapeutics Incorporated (CORT), the $135 level stands out as the most ambitious among actively published Wall Street forecasts. Canaccord Genuity analyst Edward Nash raised his target to $135 in May 2026, citing confidence in the company's relacorilant regulatory pathway and the commercial potential of Lifyorli. With the stock closing at $95.36 on July 24, 2026, a move to $135 would represent a gain of roughly 42% and would establish a new all-time high, eclipsing the prior record of $114.22 set in March 2025.
Corcept Therapeutics is a commercial-stage biopharmaceutical company focused on developing medications that modulate the cortisol hormone to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders. The company's flagship product, Korlym (mifepristone), remains the foundation of its revenue base, generating sales for the treatment of hypercortisolism, also known as Cushing's syndrome. With a market capitalization of approximately $10.24 billion, Corcept has expanded its pipeline to include relacorilant, dazucorilant, and miricorilant, targeting indications ranging from ovarian cancer to ALS (amyotrophic lateral sclerosis) and MASH (metabolic dysfunction-associated steatohepatitis).
Several catalysts could propel CORT toward the $135 target. The FDA approved Lifyorli (relacorilant) in combination with nab-paclitaxel for platinum-resistant ovarian cancer in early 2026, supported by Phase 3 ROSELLA trial data showing a 35% reduction in the risk of death. Management guided 2026 revenue to a range of $950 million to $1.05 billion and has projected that the Cushing's syndrome franchise could grow to at least $2 billion annually by decade's end, while Lifyorli alone could exceed $1 billion in U.S. annual revenue over the same period.
Additionally, Corcept resubmitted its New Drug Application (NDA) for relacorilant in Cushing's syndrome to the FDA, and the agency is expected to complete its review within approximately six months. A second approved indication for relacorilant would significantly expand the addressable market. Meanwhile, Phase 2 data for dazucorilant in ALS demonstrated an 84% reduction in the risk of death at one year, supporting plans for a registrational Phase 3 trial. These pipeline developments, combined with a debt-free balance sheet holding over $515 million in cash and investments, provide financial flexibility to fund growth.
The path to $135 is not without significant headwinds. A federal court ruling allowed Teva Pharmaceutical Industries (TEVA) to launch a generic version of Korlym, introducing direct competition to Corcept's core revenue driver. While management has maintained that its endocrine business remains robust, the generic threat could compress margins and slow revenue growth in the company's most established segment.
Valuation also presents a challenge. At $95.36, the stock trades at a trailing P/E ratio of roughly 237 and a forward P/E near 68, reflecting high growth expectations that leave little room for disappointment. Several analysts, including Piper Sandler with an $88 target and UBS with a $72 target, maintain more conservative outlooks, suggesting the market may already be pricing in significant pipeline success. The wide dispersion among analyst targets — from $72 to $135 — underscores the uncertainty surrounding Corcept's execution timeline.
From a technical standpoint, CORT has rallied powerfully from its 52-week low of $28.66 in February 2026 to current levels near $95, gaining over 230% in roughly five months. The stock's 52-week high of $97.63 represents the first critical resistance zone. A decisive breakout above that level would open the door toward the psychologically significant $100 round number. Beyond that lies the all-time high at $114.22, where sellers previously emerged in early 2025. Only after reclaiming those levels could the stock realistically challenge the $135 target. On the downside, the $80 to $88 range, which encompasses multiple analyst fair-value estimates, should act as a key support zone.
The analyst community remains broadly constructive but far from unanimous. Among the four to six analysts actively covering the stock, the consensus rating is a "Buy," with an average 12-month price target of approximately $106. Canaccord Genuity holds the high target at $135, while Piper Sandler sits at $88 and UBS at $72. H.C. Wainwright raised its target to $95 in mid-2026. The gap between the most bullish and most bearish targets — over $60 — reflects genuine disagreement about how quickly new indications will contribute to revenue and how sustainable Korlym's franchise remains in the face of generic competition.
For traders seeking a data-driven edge, Tickeron's AI Daily Buy/Sell Signals provide continuous monitoring of thousands of stocks and ETFs, including Corcept Therapeutics. The platform uses artificial intelligence to analyze shifting market conditions, technical patterns, and broader market behavior to generate actionable Buy, Sell, or Hold signals. By distilling complex market data into clear signals, the tool helps traders identify emerging opportunities, track existing positions, and respond to changing trends without manually scanning hundreds of charts. Explore how AI-driven insights can complement your own research process.
The $135 price target for Corcept Therapeutics appears achievable but demanding — requiring near-flawless execution across multiple fronts. The strongest arguments for reaching this level rest on the commercial uptake of Lifyorli, a favorable FDA decision on the relacorilant NDA for Cushing's syndrome, and continued revenue momentum that meets or exceeds the company's ambitious guidance. Conversely, the primary risks center on generic erosion of Korlym, slower-than-expected adoption of new therapies, and a valuation that already embeds substantial optimism. Investors should monitor upcoming earnings releases, regulatory decisions, and commercial prescription data as the most important signposts for whether the journey toward $135 remains on track.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CORT has been loosely correlated with VTVT. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if CORT jumps, then VTVT could also see price increases.
| Ticker / NAME | Correlation To CORT | 1D Price Change % | ||
|---|---|---|---|---|
| CORT | 100% | -3.24% | ||
| VTVT - CORT | 49% Loosely correlated | -1.01% | ||
| TENX - CORT | 41% Loosely correlated | -9.27% | ||
| AGIO - CORT | 41% Loosely correlated | -8.34% | ||
| ARCT - CORT | 37% Loosely correlated | -2.70% | ||
| AXON - CORT | 36% Loosely correlated | +0.47% | ||
More | ||||